We have been active in the field of transcutaneous vagus nerve stimulation for many years. Our current tVNS® E device is the first and currently only medical device that is certified in accordance with the European Medical Device Regulation MDR EU 2017/745 for the treatment of symptoms of sympathovagal imbalance. The tVNS® E is a medical device in risk class IIa. It is approved for the treatment of anxiety disorders, atrial fibrillation, autism, cognitive impairment, depression, epilepsy, chronic inflammatory bowel disease (including ulcerative colitis and Crohn’s disease), migraine, Parkinson’s disease, Prader-Willi syndrome, sleep disorders, systemic sclerosis and tinnitus.
In addition to the tVNS E device, we also offer a research device. The tVNS® R device offers full wireless programmability for comprehensive clinical studies. With the tVNS® Research and tVNS® Patient apps, stimulation parameter adjustment, data acquisition and patient feedback can be seamlessly integrated. For the implementation of clinical trials, we also offer a comprehensive CB safety report for obtaining approvals from ethics committees and access to a global network of experts. Since the beginning of 2025, we have also been offering the tVNS® Triggerbox. The tVNS® trigger box is a wired system that reproducibly stabilises latencies and fluctuations. Thus, tVNS® with closed loop or triggered tVNS® can be realised in a scientific setup. These research solutions are used in research projects worldwide.
